comparison of glp-1 integrated weight management platforms Virta Health announces first-of-its-kind peer-reviewed study proving its approach is an effective off-ramp from GLP-1s for sustained loss Comparing GLP-type therapies for weight
Description
Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials
GLP-1 nausea vs DPP4 neutral GI
PlexusDx helps patients navigate these interactions with personalized compounded therapy
Specific products are discussed, including dosing and side effects
A new study found that the cost of GLP-1 drugs like Wegovy and Zepbound is too high to justify their benefits
Studies show GLP-1 reduces glucagon levels and improves glucose regulation
